Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT-2 Inhibitors

Starting soon · Phase 2

Conditions studied: Type 1 Diabetes, Type 2 Diabetes

In brief

The purpose of this research is to see how well a special education plan using continuous ketone monitoring (DGK) works to lower the risk of a condition called diabetic ketoacidosis (DKA) in people with type 1 diabetes (T1D) taking SGLT2 inhibitors (a type of medication commonly used to treat type 2 diabetes). This special education plan is compared to a general education plan and considers the higher risk of DKA when using medicines like SGLT2 inhibitors.

Key facts

Study ID

NCT07421518

Run by

AdventHealth Translational Research Institute

People needed

75

Starts

2026-06-01

Expected to finish

2030-04-01

Last updated by the study team

2026-02-19

Who can join

Age: 18 and older, up to 40. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Men and nonpregnant women ≥18 years and older
• Diagnosis of T1D according to American Diabetes Association (ADA) criteria
• HbA1c < 9 %
• Participants treated with multiple daily injections of insulin, insulin pump, or advanced insulin delivery systems
• Has provided written informed consent to participate in the study.
• Must be willing to wear the investigational device
• Use of adequate contraception for the duration of the study by women of childbearing potential

You may not qualify if…

• Pregnancy, lactation or planning to become pregnant
• Any form of diabetes other than T1D
• People with T1D using weekly insulin (when approved)
• Use of sodium-glucose cotransporter 2 inhibitors within 4 weeks prior to screening
• Chronic systematic corticosteroids (>4 consecutive weeks) within 6 months before screening
• History of diabetic ketoacidosis within 6 months of screening
• History of multiple (≥ 3 infections) genital mycotic infections within 6 months of screening
• Hypotension at screening is defined as systolic blood pressure < 90 and diastolic blood pressure < 60 with symptoms of low blood pressure (confusion, dizziness, lightheadedness, fainting, heart palpitations)
• History of a level 3 hypoglycemic event (as defined by ADA criteria) within 3 months of screening
• Recent myocardial infarction, stroke, hospitalization for unstable angina or heart failure within 3 months prior to screening
• New York Heart Association Class IV heart failure
• CKD-EPI estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m²
• Impairment of systems and organs that may increase their risk of participating in the intervention study or compromise the results (for example: end stage kidney disease, active liver dysfunction, gastroparesis, anemia, ), organ transplant.
• Cancer treatment (excluding non-melanoma skin cancer treated by excision, carcinoma in situ of the cervix or uterus, ductal breast cancer in situ, resected non-metastatic breast or prostate cancer) within one year of screening
• Active Hepatitis B or C, acquired immunodeficiency syndrome (HIV infection controlled with suppressive medications is allowed) or tuberculosis
• Abnormal liver function at screening defined as any of the following: aspartate aminotransferase (AST) >2X upper limit of the normal reference range (ULN), ALT >2X ULN, serum total bilirubin (TB) >1.5X ULN
• Current or past history of decompensated cirrhosis (defined as variceal bleeding, ascites, or hepatic encephalopathy), and/or known diagnosis of cirrhosis
• Heavy alcohol use (for men, ≥5 drinks on any day or ≥15 drinks per week; for women, ≥4 drinks on any day or ≥8 drinks per week) at screening, history of alcohol use disorder or binge drinking
• Any condition or factor that would compromise the participant's safety or the scientific integrity of the study (cognitive impairment, bipolar disorder, or history of eating disorder)
• Inability to perform the study follow up/ unwilling to wear the investigational device
• People who are unwilling to consume at least 20% of calories from carbohydrates

Where it is running

• AdventHealth Translational Research Institute — Orlando, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.